| Basics |
Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders.
|
| IPO Date: |
May 1, 2012 |
| Sector: |
Healthcare |
| Industry: |
Drug Manufacturers |
| Market Cap: |
$1.88B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.47 | 2.01%
|
| Avg Daily Range (30 D): |
$0.36 | 1.10%
|
| Avg Daily Range (90 D): |
$0.43 | 1.35%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.47M |
| Avg Daily Volume (30 D): |
.59M |
| Avg Daily Volume (90 D): |
.44M |
| Trade Size |
| Avg Trade Size (Sh.): |
91 |
| Avg Trade Size (Sh.) (30 D): |
52 |
| Avg Trade Size (Sh.) (90 D): |
47 |
| Institutional Trades |
| Total Inst.Trades: |
4,276 |
| Avg Inst. Trade: |
$1.66M |
| Avg Inst. Trade (30 D): |
$2.58M |
| Avg Inst. Trade (90 D): |
$2.54M |
| Avg Inst. Trade Volume: |
.06M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.96M |
| Avg Closing Trade (30 D): |
$4.07M |
| Avg Closing Trade (90 D): |
$3.54M |
| Avg Closing Volume: |
63.88K |
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q4 2024 |
|
Basic EPS
|
$1.13
|
$-.21
|
$.28
|
|
Diluted EPS
|
$1.11
|
$-.21
|
$.27
|
|
Revenue
|
$ 668M
|
$ 149.82M
|
$ 174.16M
|
|
Gross Profit
|
$ 590.64M
|
$ 134.06M
|
$ 148.06M
|
|
Net Income / Loss
|
$ 61.91M
|
$ -11.83M
|
$ 15.33M
|
|
Operating Income / Loss
|
$ 74.56M
|
$ -10.26M
|
$ 21.41M
|
|
Cost of Revenue
|
$ 77.36M
|
$ 15.76M
|
$ 26.1M
|
|
Net Cash Flow
|
$ 52.45M
|
$ 46.52M
|
$ 37.66M
|
|
PE Ratio
|
29.59
|
|
|
|
|
|
